However, despite the successes observed in trials such as CANTOS, ASSAIL-MI, and MRC-ILA, several drawbacks were noted for most of these drugs, including high costs, adverse effects, such as sepsis and pneumonia, and administration routes. The gene discussed is TNFRSF9; the disease is pneumonia.